175717-75-6

Usage

Uses

Used in Organic Synthesis:
(S)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethylamine is used as a protecting group for the amine functionality in organic synthesis. The silicon atom serves this protective role by preventing unwanted reactions from occurring during chemical processes. This feature is particularly valuable in the synthesis of complex organic molecules where selectivity and control over the reaction are crucial.
Used in Enhancing Reactivity and Selectivity:
The presence of the tert-butyl group in (S)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethylamine provides steric hindrance, which can significantly influence the reactivity and selectivity of the compound in various chemical reactions. This steric effect can be exploited to direct reactions towards the formation of specific products, making the compound a valuable tool in the hands of synthetic chemists.
Used in Synthetic Transformations:
The ethylamine group in (S)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethylamine imparts basicity and nucleophilicity to the compound, making it useful in a variety of synthetic transformations. These transformations can include the formation of new carbon-carbon bonds, the introduction of functional groups, or the modification of existing functional groups within a molecule. (S)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-ethylamine's ability to participate in such reactions broadens its utility in organic chemistry and contributes to its status as a versatile compound.

Upstream product

• 2749-11-3 (S)-Alaninol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 923579-14-0 methyl (R)-2-benzyl-3-[(S)-2-(tert-butyldimethylsilyloxy)-1-methyl-ethylamino]-2-(2-nitrobenzenesulfonylamino)-propanoate 
• 1415379-93-9 C₂₀H₃₅N₃O₇SSi 
• 1258855-79-6 2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-N-((1S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)acetamide 
• 1109277-57-7 methyl trans 2S-(4-(4-(1-(tert-butyldimethylsilyloxy)propan-2-ylamino)phenyl)cyclohexyl)acetate 
• 923579-20-8 (3R)-3-benzyl-1-[(1S)-2-(tert-butyldimethylsilyloxy)-1-methylethyl]-3-(2-nitrobenzenesulfonylamino)-azetidin-2-one 

Relevant academic research and scientific papers

Development and Mechanistic Interrogation of Interrupted Chain-Walking in the Enantioselective Relay Heck Reaction

The formation of alkyl-palladium complexes via the nucleopalladation of alkenes is the entry point for a wide range of diverse reactions. One possibility is that the intermediate alkyl-Pd complexes can undergo a "chain-walking"event, to allow for remote functionalization through various termination processes. However, there are few methods to selectively interrupt the chain-walking process at a prescribed location. Herein, we demonstrate that a variety of homoallylic protected amines undergo an interrupted enantioselective relay Heck reaction to give enantioenriched allylic amine products. The selectivity of this process can be diverted to exclusively yield the ene-amide products by virtue of changing the nature of the amine protecting group. To rationalize this observation, we combine experiment and computation to investigate the mechanism of the chain-walking process and termination events. Isotopic labeling experiments and the computed reaction pathways suggest that the system is likely under thermodynamic control, with the selectivity being driven by the relative stability of intermediates encountered during chain-walking. These results illustrate that the chain-walking of alkyl-palladium complexes can be controlled through the alteration of thermodynamic processes and provides a roadmap for exploiting these processes in future reaction development.

NOVEL STING AGONISTS

The present invention provides compounds of Formula I′: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

NOVEL N-(2,2-DIFLUOROETHYL)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES

The present invention relates to novel N-(2,2-difluoroehtyl)-N-[(Pyrimidinylamino)propanyl]- arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

Chirality n-heterocyclic carbine precursor compound with benzoglioxaline frameworks and preparation method and application thereof

The invention discloses chirality n-heterocyclic carbine precursor compound with benzoglioxaline frameworks and a preparation method and application thereof. Five steps of reaction can simply and effectively compound a series of chirality benzoglioxaline

PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease, in particular influenza.

NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.

NOVEL N-[(PYRAZINYLOXY)PROPANYL]BENZAMIDES

This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, Rsu

NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

Addition of allylzinc to a-amino acid-derived imines: Synthesis of diamino alcohols by Hydroboration

Imines obtained by condensation of Z-pro- tected or Boc-protected α-amino aldehydes with α-amino tert-butyl esters or with O-silyl-protected amino alcohols were reacted with preformed allyl zinc yielding homoal- lylamines with yields around 50% and selectivities ranging from 50:50 to 90:10. Hydroboration of the terminal double bond furnished diamino alcohols with yields up to 97%. The configuration of the substrates was determined by X-ray-crystallographic analysis of a hydroboration product and comparison of physical data. Springer-Verlag 2010.